FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting
This article was originally published in The Rose Sheet
In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.
You may also be interested in...
Under current cosmetics regulations FDA does not have the authority to order product recalls, as it does in the dietary supplement space, for example. Voluntary cosmetic recalls have been typically light in recent months, most often citing microbiological issues.
President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.
FDA’s Office of Cosmetics and Colors is heading up laboratory studies to explore an issue central to rampant litigation – talc’s effects on female genital system tissues, supported by a grant from the agency’s Office of Women’s Health. The agency is still finalizing a scientific literature review, but expects its research will help fill gaps that have not been adequately covered by epidemiologic and animal studies to date.